Meliglix

Sitagliptin, the active ingredient in Meliglix, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It works by increasing incretin levels, thereby enhancing insulin secretion and reducing glucagon release, and is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets. Our distribution network ensures timely delivery and regulatory compliance for all customers.

Meliglix (sitagliptin) is used in the management of type 2 diabetes, a chronic metabolic disorder affecting glucose regulation.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise. - Monotherapy in adults: provides glycemic control as an initial oral agent for patients intolerant to metformin. - Combination therapy with metformin: enhances overall glucose‑lowering effect in patients requiring additional control.

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain indicating pancreatic inflammation. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain (arthralgia): persistent musculoskeletal discomfort.

When prescribing Meliglix, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes during therapy. - History of pancreatitis: avoid use due to risk of recurrence. - Concomitant insulin or sulfonylureas: increased risk of hypoglycemia, monitor glucose levels. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with insulin or sulfonylureas: may cause significant hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations. - ACE inhibitors or ARBs: monitor renal function when combined in patients with kidney disease. - Warfarin: occasional alterations in INR, require periodic monitoring.